The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities. Objectives: Limited data exist on the adoption ...
Uterine artery embolization (UAE) is a technique used by interventional radiology specialists. It was introduced several decades ago for the treatment of massive uterine hemorrhages due to various ...
The regulatory environment has become increasingly supportive of multi-indication development. A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have ...
Of the 53 facilities that participated in this study, 81.1% were VHA members, 17% were UHC members, and 1.9% were members of both VHA and UHC. Data were collected from a total of 1672 patients; 938 ...
MOUNTAIN VIEW, Calif., Jan. 9, 2012 -- /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that following recent discussions with Food and Drug Administration (FDA) officials, the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback